Acadia Pharmaceuticals
(ACAD) 1.03

3911 Sorrento Valley Blvd., San Diego, CA 92121

ACADIA Pharmaceuticals is a drug discovery and development company that efficiently identifies small molecule drug candidates using its proprietary chemical-genomics platform. We are developing a portfolio of clinical-stage drug candidates aimed at large market opportunities in schizophrenia, Parkinson's disease, and other central nervous system disorders. We currently have five drug programs in clinical and preclinical development. Our three Phase II-stage clinical programs, for which we have retained worldwide commercialization rights, are ACP-103 for treatment-induced dysfunction in Parkinson's disease, ACP-103 as an adjunctive therapy for schizophrenia, and ACP-104 for treatment of schizophrenia. We have additional clinical and preclinical drug development programs in the areas of neuropathic pain and glaucoma, respectively, in collaboration with Allergan, Inc.ACADIA's corporate headquarters as well as its genomics and biological research facilities are located in San Diego, California. ACADIA also maintains chemistry research facilities in Copenhagen, Denmark.

ACON Laboratories

4108 Sorrento Valley Blvd, San Diego, CA 92121

ACON Laboratories manufactures medical rapid tests in the form of strips, midstreams, panels, and devices under the ACON brand and for private label. Our rapid test kits are used to test for Drugs of Abuse, Pregnancy (hCG) and Ovulation, Tumor/Cardiac Markers, and Infectious Diseases such as H. pylori, Chlamydia, Syphilis, Malaria, HIV, HCV, Strep A, Hepatitis (HBsAb, HBsAg, HBcAb, HBeAb, HBeAg). Many of our tests are CE Marked for sale in the European Community. A recent addition to our product line is a blood Glucose monitoring system.

ActivX

11025 North Torrey Pines Rd, Suite 120, La Jolla, CA 92037

Activity-based Proteomics. ActivX Biosciences is pioneering the field of activity-based proteomics to increase the speed and cost-effectiveness of target discovery and drug development. The company is developing a high-throughput chemistry platform for identifying and analyzing active proteins in all ranges of abundance in any biological sample. Current genomics and proteomics technologies do not report on protein activity - an end-stage event that regulates both health and disease. By providing the first global analysis of protein activities, ActivX's next-generation proteomics approach addresses the gap between the data generated by standard genomics and proteomics techniques and the therapeutic relevance of those data. The core of ActivX technology is based on the design and synthesis of novel chemical probes that can rapidly and directly interrogate the activities of key protein families. These proprietary chemical probes permit the quantitation of changes in protein activities in any cell type and tissue over a range of normal and pathological conditions.

ADVENTRX Pharmaceuticals, Inc.
(ANX) 1.85

6725 Mesa Ridge Rd., Suite 100, San Diego, CA 92121

ADVENTRX Pharmaceuticals is dedicated to creating anticancer and antiviral research developments that dramatically influence the fight against life-threatening diseases such as cancer and serious viral infections. The Company's products are intended to refine current cancer and antiviral therapies, while addressing specific problems such as drug resistance.

Aegis Therapeutics, LLC

16870 West Bernardo Drive, Suite 390, San Diego, CA 92127

Aegis Therapeutics is a specialty pharmaceutical company commercializing advanced patented drug delivery technologies that enable the non-invasive delivery of a broad range of protein, peptide, and non-peptide macromolecular therapeutics. Our goal is to broadly enable intranasal and transmucosal delivery of peptide and protein drugs across a wide spectrum of disease categories for the world’s current and future leading pharmaceutical and biopharmaceutical companies.

Althea Technologies

3550 General Atomics Ct, Building #2, San Diego, CA 92121

Althea Technologies, Inc.is a leader in offering highly specialized custom genomic analyses and cGMP contract manufacturing for genetic vaccine and gene therapy products. The privately owned company was formed with the aim of accelerating gene-based drug development by supporting researchers worldwide in the biopharmaceutical industry in their attempts to understand the mechanisms of disease and develop new therapeutics.

Ambit Biosciences Corp.

875 Towne Centre Dr., San Diego, CA 92121

Ambit utilizes its technology to directly identify the authentic protein target or targets for compounds that elicit therapeutically relevant responses in organisms or assays through unknown mechanisms of action. Discovery of the identity of drugable targets for marketed compounds with unknown mechanisms of action provides Ambit with the unprecedented opportunity to exploit protein targets that are already therapeutically and commercially validated. Such validated targets are tremendously valuable to Ambit and its pharmaceutical partners because they are far more likely to lead to new, commercially successful drugs. This is because new compounds directed against already validated targets are likely to have lower rates of attrition as they move through the development process than compounds directed against previously unprecedented, non-validated targets. The same ideas apply for protein target discovery using biologically or pharmaceutically active compounds that have not yet been commercialized. Ambit can apply its technology to identify the protein targets of compounds that have interesting biological or pharmacological activities in cell-based or animal-based tests, but for which the mechanisms of action are unknown. Ambit's approach for identifying human proteins that bind small molecules or peptides is based upon the combination of protein phage display and affinity chromatography. This proprietary method, termed ProteomeScan?, employs a novel twist on conventional phage display methodology that allows Ambit to interrogate large and diverse collections of proteins simultaneously.

Amylin Pharmaceuticals Inc
(AMLN) 21.84

9360 Towne Ctr Dr, Suite 110, San Diego, CA 92121

Amylin Pharmaceuticals is involved in discovering, developing and commercializing potential drug candidates for the treatment of metabolic disorders. The Company develops SYMLIN, which is a synthetic analog of the human hormone, amylin, invented by the Company's scientists, for the treatment of the people with diabetes who use insulin. The Company is developing drug candidates AC2993, a code name for synthetic exendin-4, for the treatment of type 2 diabetes and AC3056, used in the treatment of metabolic disorders relating to cardiovascular disease.

Anadys Pharmaceuticals
(ANDS) 1.78

9050 Camino Santa Fe, San Diego, CA 92121

Anadys Pharmaceuticals, Inc. is a new generation drug discovery company committed to the translation of genomic information into small molecules. The company employs proprietary technologies in microbial genomics (GATE), affinity-based compound screening against targets of both known and unknown function (ATLASô), world-class high-output medicinal chemistry, and cheminformatics including proprietary software (PROTOSô) to develop a portfolio of novel anti-infective products. The company also intends to become a sector leader in the emerging field of Riboproteomicsô, the study of RNA-protein interactions and the development of novel therapeutic compounds that target these interactions.

Angstrom Pharmaceuticals

10655 Roselle Street, Suite G San Diego, CA 92121

Angstrom Pharmaceuticals is committed to discovering drugs that block the docking of an extracellular regulatory protein (ligand) to its receptor found on the outside of a cell when this event is responsible for initiating a disease state. Receptors can be identified that trigger several intractable diseases including cancer, the first focus of the Company's mission. Angstrom targets a receptor for blockade only following a detailed analysis of that receptorís role in the disease. The blocking drugs are designed such that they can easily reach their site of action and have minimal side effects.

Arena Pharmaceuticals Inc
(ARNA) 7.24

6166 Nancy Ridge Dr, San Diego, CA 92121

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative oral drugs to benefit patients with serious diseases and disorders. Our lead independently developed drug candidate, lorcaserin hydrochloride, is intended for the treatment of obesity and is being evaluated in a Phase 3 clinical program. We also have other proprietary programs, such as programs intended to address insomnia and arterial thrombosis.

Attenuon

11535 Sorrento Valley Road, Suite 401, San Diego, CA 92121

Attenuon is developing a new generation of cancer therapeutics. These therapies work by selectively disrupting cellular signaling processes important to tumor growth and metastasis (the spreading of tumors), rather than indiscriminately killing both malignant and normal cells undergoing cell division. Based on this approach, Attenuon is working to develop therapies that are effective against many types of cancer, produce few side effects, are less prone to acquired drug resistance, are suitable for long-term use, and work well with existing therapies.

Avanir Pharmaceuticals
(AVNR) 2.72

11388 Sorrento Valley Rd, San Diego, CA 92121

AVANIR PHARMACEUTICALS is a publicly held California corporation (AVN) formed in 1988 and publicly traded since 1990. Our lead product, AbrevaTM, a topical treatment for cold sores, was approved by the U.S. Food and Drug Administration in July 2000. It is the only FDA-approved product available without prescription in the over-the-counter (OTC) market. GlaxoSmithKline, one of the world's largest pharmaceutical companies, is our marketing partner in the US and Canada. The company's product development pipeline includes an in-licensed drug, Neurodex, for the treatment of emotional lability in neurodegenerative diseases. The company also has a drug discovery program in the advanced pre-clinical stage of development for the treatment of the underlying biological causes of allergy and asthma. Other areas of development include our patented fully human monoclonal antibody technology, clinical development work on genital herpes, and preclinical work on cholesterol lowering and inflammation.

Avera Pharmaceuticals

12730 High Bluff Drive, Ste. 160, San Diego, CA 92130

Avera is a neuroscience specialty pharmaceutical company focused on the acquisition, development and commercialization of novel pharmaceutical compounds. Avera’s greatest strength and expertise is in drug development. Currently, the company is developing a pipeline of drug candidates to treat Social Anxiety Disorder, Irritable Bowel Syndrome, Overactive Bladder, Cognitive Impairment Associated with Schizophrenia, and Dementia, as well as a neuromuscular blocking agent for both rapid and routine endotracheal intubation and skeletal muscle relaxation during surgery.

AVIVA Biosciences

11180 Roselle Street, Suite 200, San Diego, CA 92121

AVIVA Biosciences Corporation develops enabling drug discovery technologies by combining biochips with cell biology. Key application areas include electrophysiology research, ion channel drug screening and rare-cell isolation.

Biocept, Inc.

5810 Nancy Ridge Drive, Suite 150, San Diego, CA 92121

Biocept engineers novel solutions that provide the foundation for a new class of diagnostic assays. The CEE™ Cell Enrichment and Extraction platform combines sophisticated attachment chemistry with mathematically modeled fluid dynamics. The proprietary technology enables earlier, accurate, less invasive diagnoses. Isolation, purification and analysis of rare cells are managed within our state-of-the-art CLIA-accredited laboratory. The first application of CEE technology, FirstCEE is a prenatal test that collects fetal cells from a maternal blood sample. FirstCEE is designed to enrich samples of fetal nucleated red blood cells from maternal blood, and extract these cells for analysis. This first trimester, non-invasive test will analyze aneuploidies of chromosomes 21, X and Y. This approach eliminates the risks of an invasive procedure such as amniocentesis or chorionic villus sampling (CVS).

Biogen IDEC
(BIIB) 57.17

14 Cambridge Center Cambridge, MA 02142 3030 Callan Rd, San Diego, CA 92121

In November 2003, Biogen Idec Inc. was formed from the merger of two of the world’s leading biotechnology companies, Biogen, Inc. and IDEC Pharmaceuticals Corporation. This combination has resulted in a fusion of complementary strengths in therapeutic focus, research and development capabilities, manufacturing expertise, global infrastructure, and financial position. Biogen Idec intends to continue its growth through discovery, development and commercialization of its own innovative products and through strategic alliances as the partner-of-choice for biologics development, manufacturing and marketing. Biogen Idec is dedicated to pursuing the creativity of science. The company’s products and development programs address a variety of key medical needs in the areas of oncology, neurology, dermatology and rheumatology.

Biosite Inc

11030 Roselle St, San Diego, CA 92121

Biosite, Inc. is involved in the development, manufacture and marketing of rapid, accurate and cost-effective diagnostic products that improve the quality of patient care and simplify the practice of laboratory medicine through several product platforms: Triage Panel for Drugs of Abuse is capable of detecting a broad spectrum of commonly overdosed prescription and illicit drugs in approximately 10 minutes; Triage C. DIFFICILE Panel is designed to identify CLOSTRIDIUM DIFFICILE, an opportunistic pathogen of the intestinal tract that may thrive as a result of broad spectrum antibiotic treatment; Triage Parasite Panel is designed to simultaneously detect three common waterbone parasites, GIARDIA LAMBLIA, CRYPTOSPORIDIUM PARVUM and ENTAMOEBA HISTOLYTICA/DISPAR, that can cause severe gastrointestinal infections; and Triage Cardiac System aids in the diagnosis of acute myocardial infarction, commonly known as heart attacks.

Ceregene

9381 Judicial Dr., Ste. 130, San Diego, CA 92121

Ceregene is focused on developing neurotrophic growth factor treatments for major neurodegenerative disorders using a proprietary gene delivery technology. In its short history, Ceregene has already brought gene therapy products for Alzheimer’s disease and Parkinson’s disease through pre-clinical development and into clinical trials. Ceregene also has research programs investigating therapies for other neurodegenerative disorders for which no effective treatment exists, such as amyotrophic lateral sclerosis (ALS), ocular diseases such as retinitis pigmentosa (RP), age-related macular degeneration (AMD), and glaucoma, and Huntington’s disease. Ceregene’s gene therapy vectors deliver naturally occurring neurotrophic factors that slow or halt the neurodegeneration that underlies neurological disorders. Ceregene designs its therapies to slow, halt or possibly reverse neuronal degeneration, as opposed to currently accepted methods that merely try to compensate for loss of function. Using Ceregene’s technology, only a single treatment will be necessary to provide long-term therapy to degenerating nerve cells.

Cylene Pharmaceuticals

5820 Nancy Ridge Drive, Suite 200, San Diego, CA 92121

Cylene Pharmaceuticals is a private company devoted to the discovery, development and commercialization of first-in-class small molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. Our pharmaceutical pipeline is led by CX-3543, which demonstrates potent in vivo efficacy in xenograft models of human solid tumors and is in formal preclinical development. CX-3543 blocks production of multiple oncogenes including VEGF and c-Myc, both widely recognized tumor targets.

Cyntellect

6620 Mesa Ridge Road, Suite 100, San Diego, CA 92121-2906

Cyntellect is a company dedicated to commercializing platform solutions and services, that will enable scientists to efficiently and accurately exploit living cells. The company has launched commercial products and services and has established business relationships with leading academic and commercial institutions in life sciences.

Cypress Bioscience
(CYPB) 3.37

4350 Executive Drive, Suite 325, San Diego, CA 92121

We are committed to being the innovator and leader in providing products for the treatment of patients with Functional Somatic Syndromes, such as Fibromyalgia Syndrome, or FMS, and other central nervous system disorders. Specifically, our strategy involves acquiring or in-licensing central nervous system, or CNS, active compounds and developing them for novel and typically underserved indications. The term Functional Somatic Syndromes refers to several related syndromes characterized more by symptoms, suffering and disability than by disease specific abnormalities that are found upon physical examination and include many overlapping pain and psychiatric conditions. We pursue opportunities to acquire or in-license CNS active compounds in the areas in which the brain and body overlap, where CNS mechanisms have a strong influence on somatic or bodily symptoms, and our ongoing development program is representative of this strategy.

Elan Corporation, plc
(ELN) 4.65

Lincoln Place Lincoln House, Dublin IRELAND 22 7475 Lusk Blvd, San Diego, CA 92121

Elan Pharmaceuticals is primarily involved in the discovery, development and marketing of products in the therapeutic areas of neurology, pain management, oncology, infectious diseases and dermatology. Clinical development programs are ongoing in the fields of Alzheimer's disease, multiple sclerosis (MS), inflammatory bowel disease, Parkinson's disease, spasticity and oncology.

EpiCept Corp
(EPCT) 0.61

777 Old Saw Mill River Road Tarrytown, NY 10591 6650 Nancy Ridge Drive San Diego, CA 92121 Goethestraße 4 D-80336 Munich, Germany

EpiCept is focused on developing novel, effective, safe and economical prescription pain products delivering drugs to a target area by using a topical delivery approach as opposed to systemic or transdermal modes.

Favrille, Inc.
(MMRF.OB) 0.09

10445 Pacific Center Court, San Diego, CA 92121

We are a biopharmaceutical company focused on the development and commercialization of patient-specific immunotherapies for the treatment of cancer and other diseases of the immune system. We own a proprietary technology that enables us to efficiently develop and manufacture active immunotherapy products designed to stimulate a patient's own immune system to mount a specific and sustained response to disease. Our lead product candidate, FavId®, is an active immunotherapy for the treatment of B-cell non-Hodgkin's lymphoma.

Gen-Probe, Inc.
(GPRO) 46.70

10210 Genetic Center Dr, San Diego, CA 92121

The mission of Gen-Probe is to be the world leader in nucleic acid diagnostics for human disease. Since 1985, when we received clearance to market the first clinical diagnostic test using a DNA probe, we have set the standard for the diagnostic industry's use of DNA probe technology. We continue to strive to be the world leader in nucleic acid diagnostics.

Genomatica, Inc.
*SERVICE*

5405 Morehouse Drive, Suite 210, San Diego, CA 92121

Genomatica is forging new ways to transform living cells into biological factories (Bio-Factories) for the manufacture of valuable chemical and biological products. We employ a unique and powerful Integrated Metabolic Engineering Platform to design, engineer, and optimize Bio-Factories with superior performance characteristics. This revolutionary approach dramatically reduces development timelines and costs, while greatly improving productivities, product yields and overall process economics. Genomatica’s novel Bio-Factories are now unlocking large market and emerging product opportunities in the chemical, material, pharmaceutical, and energy industries.

Genoptix
*SERVICE*
(GXDX ) 18.02

2110 Rutherford Road, Carlsbad, CA 92008

Genoptix, Inc., a CLIA and CAP certified laboratory provides Personalized Medicine Services to hematologists and oncologists that combine proprietary and exclusive tests with advanced clinical techniques for comprehensive evaluation of individual patients.

Halozyme Therapeutics
(HALO) 7.51

11588 Sorrento Valley Road, San Diego, CA 92121

Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's first hyaluronidase enzyme, recombinant human PH20 or rHuPH20, is the platform for three different products, including a medical device, a drug enhancement agent, and a therapeutic biologic. The company's initial products are being developed to offer safer and purer alternatives to existing slaughterhouse-derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity.

Hollis-Eden Pharmaceuticals
(HRBR) 0.25

4435 Eastgate Mall, Suite, 400, San Diego, CA 92121

Hollis-Eden Pharmaceuticals, Inc. is the world leader in the development of a proprietary class of adrenal steroid hormones as novel pharmaceuticals for human health. Through its Hormonal Signaling Technology Platform, Hollis-Eden is developing a new series of small molecule compounds that are metabolites or synthetic analogs of endogenous hormones, derived by the adrenal glands from the body’s most abundant circulating steroid, that play a fundamental role in the chemistry of life, aging and disease. The Company’s clinical drug development candidates include HE3286, being prepared for clinical trials in treating type 2 diabetes and potentially rheumatoid arthritis, and HE3235, selected for clinical development in cancer. In addition to these clinical development candidates, Hollis-Eden has an active research program that is generating additional new clinical leads that are being further evaluated in preclinical models of a number of different diseases.

Ichor Medical Systems, Inc.

6310 Nancy Ridge Drive, Suite 107, San Diego, CA 92121

Ichor is dedicated to the clinical application and commercialization of electroporation technology for the delivery of DNA drugs and vaccines to treat and prevent debilitating or life threatening diseases. Ichor has developed a powerful, patented electroporation technology for DNA drug delivery that will generate significant value for patients, investors and partners. We are applying our proprietary TriGrid™ Delivery System (TDS) to enable delivery of DNA drugs to address unmet medical needs in areas including therapeutic cancer vaccines, therapeutic proteins and vaccines for serious infectious disease. To date, the lack of an effective clinical delivery technology has blocked the development efforts of several promising DNA drugs. The TDS device holds the key to unlocking the potential of many broad families of DNA drugs and DNA vaccines.

Illumina Inc
(ILMN) 45.00

9885 Towne Centre Drive, San Diego, CA 92121-1975 50 Barnes Park North Wallingford, CT 06492

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Immusol, Inc.

10790 Roselle Street, San Diego, CA 92121

Immusol, Inc is a privately held San Diego-based biopharmaceutical company engaged in the discovery and development of novel therapies to treat cancer, hepatitis C, and age-related macular degeneration (AMD). Immusol develops small molecule and protein-based therapies alone or in collaboration with drug development partners. Immusol's novel oncolytic viral therapy for solid tumors is expected to enter the clinic in 2007; its HCV entry inhibitor and wet AMD programs are in pre-clinical development.

Inovio Biomedical Corporation
(INO) 1.09

11494 Sorrento Valley Rd., San Diego, CA 92121-1318

Inovio Biomedical Corporation (AMEX: INO) is a late stage biomedical company developing novel therapies enabled by electroporation, with a focus on addressing critical unmet treatment needs in oncology. Clinical results validate its local cancer therapy's ability to preserve healthy tissue while selectively killing cancer cells in solid tumors. Compared to surgery, this treatment is simpler, superior in its ability to preserve tissue structure and function (providing quality of life benefits), and lower cost. Inovio's non-viral delivery platform enabled the first-ever clinical study to deliver a gene in humans using electroporation. With the validation of promising pre-clinical data and licensing agreements with Merck and Vical, the company's technology may be instrumental in achieving the potential of important therapeutic genes and DNA vaccines.

Invitrogen Corp
*VENDOR/SERVICE*
(LIFE) 46.16

1600 Faraday Avenue, Carlsbad, CA 92008

We provide products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. Our life science technologies improve and accelerate all areas of research, drug discovery, and commercial bioproduction.

Isis Pharmaceuticals, Inc.
(ISIS) 8.22

1896 Rutherford Road, Carlsbad, CA 92008-7208

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms.

Kemia, Inc.

5871 Oberlin Drive, Suite 100, San Diego, CA 92121

Kémia, Inc. is a private company that discovers and develops novel small molecule therapeutics targeting validated high value disease targets not yet addressed by safe and effective orally active drugs. Kémia's proprietary chemistries are focused in two promising areas: allosteric kinase inhibitors and modulators of G protein-coupled receptors (GPCRs). Kémia's lead compound is KC706, an orally active allosteric p38 MAP kinase inhibitor being developed for the treatment of inflammatory diseases such as rheumatoid arthritis. KC706 was shown to be well tolerated and exhibited a favorable ADME profile in Phase I clinical studies. A Phase II clinical trial in rheumatoid arthritis patients is currently in progress. A second Phase II trial, assessing the effects of KC706 on various biomarkers in patients at risk for cardiovascular disease (low HDL and elevated triglycerides) is also underway. Results from both studies and initiation of a third phase II in an orphan indication are anticipated this year. Kémia is also evaluating the feasibility of developing a topical formulation of KC706 for the treatment of inflammatory skin diseases. In addition to its clinical stage programs, Kémia has promising projects at earlier stages of development: CCR5 inhibitors (HIV/transplant rejection) and amylin receptor agonists (diabetes/obesity).

La Jolla Pharmaceutical Company
(LJPC.PK) 0.04

6455 Nancy Ridge Drive, San Diego, CA 92121

La Jolla Pharmaceutical Company is dedicated to improving and preserving human life by developing innovative pharmaceutical products. The Company's leading product in development is Riquent®, which is designed to treat lupus renal disease by preventing or delaying renal flares. Lupus renal disease is a leading cause of sickness and death in patients with lupus. The Company has also developed small molecules to treat various other autoimmune and inflammatory conditions.

Ligand Pharmaceuticals
(LGND) 1.49

10275 Science Center Drive, San Diego, CA 92121

Ligand is an early-stage biotech company that focuses on discovering and developing new drugs that address critical unmet medical needs in the areas of thrombocytopenia, cancer, hepatitis C, hormone-related diseases, osteoporosis and inflammatory diseases. The company strives to develop drugs that are more effective and/or safer than existing therapies, that are more convenient to administer and that are cost effective.

Lpath, Inc.
(LPTN.OB) 0.56

6335 Ferris Square, Suite A, San Diego, CA 92121

Lpath, Inc., headquartered in San Diego, California, is the category leader in lipidomics-based therapeutics, an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases.

Lpath's lead product candidate, ASONEP™ (the systemic formulation of Sphingomab™), is a monoclonal antibody against a validated cancer target, sphingosine-1-phosphate (S1P). ASONEP™ is potently anti-angiogenic, yet it has other mechanisms of action that may prove advantageous in the clinical setting. As such, Lpath believes ASONEP™ may represent the next generation of anti-angiogenesis-based therapeutics. ASONEP is currently being tested in Phase 1 clinical trials in cancer.

Lpath's second product candidate, iSONEP™ (the ocular formulation of Sphingomab ™), has demonstrated superior results in various preclinicial AMD models and first-in-class results in a preclinical model of ischemic retinopathy. In addition, the drug candidate has shown anti-fibrotic mechanisms that might provide comparative advantage in the AMD realm and is also suggestive of efficacy against glaucoma when surgery is required. iSONEP is currently being tested in Phase 1 clinical trials in wet AMD patients.

Lpath's third product candidate, Lpathomab™, is a monoclonal antibody against lysophosphatidic acid (LPA), a key bioactive lipid that has long been recognized as a significant promoter of cancer-cell growth and metastasis in a broad range of tumor types and a significant contributor to neuropathic pain. We have demonstrated a strong anti-angiogenic mechanism of action for Lpathomab™ and have shown encouraging results in several models of AMD and cancer.

Lpath's unique ability to generate antibodies against bioactive lipids is based on its proprietary ImmuneY2™ drug-discovery engine. The company is currently applying the ImmuneY2™ technology to other important lipid-signaling agents, thereby adding to our pipeline of novel antibody-based drug candidates.

Medigene AG

Lochhamer Str. 11, 82152 Martinsried, GERMANY 57c Milton Park, Abingdon, Oxon OX14 4RX, UK 10660 Scripps Ranch Blvd., Suite 200 San Diego, CA 92131

MediGene's vision is the expansion of the potentials in medicine by means of utilizing biotechnology in a responsible manner. We apply state-of-the-art technologies in the development of innovative drugs for the treatment of cancer and autoimmune diseases. MediGene pursues the strategy of integrating all core areas of a modern biopharmaceuticals company from research to drug development and commercialization.

Medinox, Inc.

6120 Paseo Del Norte, Suite B-2, Carlsbad, CA 92009

Medinox, Inc. is a San Diego-based pharmaceutical company that is developing new small molecule drugs to treat a wide variety of unmet medical needs including sepsis, arthritis & inflammation, diabetes and sickle cell anemia.

Metabasis Therapeutics, Inc.

11119 North Torrey Pines Road, La Jolla, CA 92037

Metabasis Therapeutics is focused on the discovery, development and commercialization of novel therapies to address some of the world's most widespread and costly chronic diseases. Metabasis has a broad product pipeline targeting large markets with significant unmet medical needs. We are specifically focused on metabolic diseases involving pathways to the liver, such as diabetes and hyperlipidemia, as well as liver diseases such as hepatitis and liver cancer. We currently have five internally discovered product candidates in clinical development as well as an active discovery team seeking additional product candidates to treat metabolic diseases.

MicroIslet, Inc.
(MIISE.OB) 0.00

6370 Nancy Ridge Drive, Suite 112, San Diego, CA 92121

MicroIslet is engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes. MicroIslet has licensed several technologies from Duke University Medical Center developed over the last decade for the isolation, culture, storage and encapsulation of insulin-producing porcine islet cells. We believe these proprietary methods are among the most important advances in the field of transplantation that may enable diabetic patients to become free from insulin injections. MicroIslet's ultimate goal is to offer a solution towards a cure for diabetes worldwide.

Micromet AG
(MITI) 6.71

Staffelseestr. 2, 81477 Munich, Germany 2110 Rutherford Road Carlsbad, CA 92008

*Acquired CancerVax in May 2006.*
Micromet's therapeutics engage 'killer cells' of the immune system to promote a deadly liaison with pathogenic cells. With BiTEô technology, Micromet is first in successfully delivering a drug format that utilizes the broad repertoire of T cells for the elimination of pathogenic cells. T cells are the most potent cytotoxic 'killer' cells of the human immune sytem. Micromet's drugs circumvent the various immune escape mechanisms of pathogenic cells and stimulate a precise and potent immune response against pathogenic cells.

Migenix

BC Research Building, 3650 Wesbrook Mall, Vancouver, B.C. V6S 2L2 Canada 12780 High Bluff Drive, Suite 210, San Diego, CA 92130

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs for the prevention and treatment of major medical diseases and certain conditions with unmet medical need. With its expertise and experience in product development, the Company is focused on advancing its pipeline of product candidates in the areas of infectious and degenerative diseases.

Mpex Pharmaceuticals, Inc.

3030 Bunker Hill Street, Suite 200, San Diego, CA 92109

Mpex Pharmaceuticals is focused on the discovery and development of new anti-bacterial drugs that meet the growing clinical need created by multi-drug resistant bacterial pathogens. It is well documented that antibiotic resistance is a growing, serious problem in both the hospital and community setting. Mpex's approach is to improve the activity of existing antibiotics by utilizing methods and potentiators to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance.

Nanogen, Inc
(NGEN.PK) 0.01

10398 Pacific Center Court, San Diego, CA 92121 21720 23rd Drive SE, #150, Bothell, WA 98021 1 Marmac Drive, Toronto, Ontario, Canada M9W 1E7 Corso Torino 89/d, 10090 Buttigliera Alta (TO), Italy

Nanogen’s technologies are uniquely bridging the gap between early-stage scientific research and actual clinical practice. We are committed to helping the healthcare community realize the benefit of molecular diagnostics and to improving patient care through advances in the diagnosis of disease and the evaluation of particular therapies for individual patients.

Nereus Pharmaceuticals

10480 Wateridge Circle, San Diego, CA 92121

Nereus Pharmaceuticals is an innovative drug discovery and development company pursuing untapped sources of chemical diversity through identifying drug candidates derived from marine microbes. With unmatched expertise in marine microbiology and integrated technologies to identify and synthesize novel biologically active compounds, the Company’s two oncology drug candidates are in Phase I clinical trials. NPI-2358, a tumor vascular disrupting agent, is being evaluated for solid tumors, and a proteasome inhibitor NPI-0052 is being developed for solid tumors, lymphomas and multiple myeloma. Nereus’ discovery portfolio also includes additional drug candidates for oncology, infectious diseases, and inflammation.

Neurocrine Biosciences, Inc.
(NBIX) 5.66

12790 El Camino Real, San Diego, CA 92130

Neurocrine Biosciences is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, irritable bowel syndrome, pain, and CNS-related disorders.

Novocell, Inc.

3550 General Atomics Court, Building 2-503, San Diego, CA 92121

Novocell’s goal is to develop a renewable source of specialized cells that can be used to treat chronic cellular diseases. To achieve this goal, Novocell is uniquely positioned to exploit human stem cell engineered product opportunities using its proprietary cell encapsulation technology. Combined with Novocell's expertise in cell transplantation, these technologies will allow large numbers of patients to be implanted with disease curing cells without the use of immunosuppression. Beginning with the treatment of diabetes, Novocell’s technology platform has wide application to a range of diseases and conditions where the only effective treatment will be the replacement of non-functional cells. These include Parkinson’s Disease, spinal cord injury, stroke, thyroid malfunction, and chronic liver failure.

Nventa Biopharmaceuticals
(NVN.TO) 0.00

9381 Judicial Drive, Suite 180, San Diego, CA 92121 #120 - 4243 Glanford Avenue, Victoria, BC Canada V8Z 4B9

Nventa Biopharmaceuticals Corporation is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The Company’s lead initiative is the development of HspE7, a therapeutic vaccine for the possible treatment of patients with cervical dysplasia, recurrent respiratory papillomatosis and genital warts.

Optimer Pharmaceuticals, Inc.
(OPTR) 8.11

10110 Sorrento Valley Rd., Suite C, San Diego, CA 92121

Optimer is currently focused on discovering, developing, and commercializing innovative anti-infective products for treating diseases that currently have no satisfactory therapy. Our initial development efforts address products that treat gastrointestinal infections and related diseases where current therapies have limitations, including diminished efficacy, serious adverse side effects, drug-to-drug interactions, difficult patient compliance and bacterial resistance. We have two late-stage anti-infective product candidates, Difimicin and Prulifloxacin. Dificimin, our lead product candidate, is an antibiotic currently in a Phase 2b/3 registration trial for the treatment of CDAD, the most common nosocomial diarrhea. Prulifloxacin is an antibiotic currently in Phase 3 trials for the treatment of travelers' diarrhea.

Orchestra Therapeutics
(OCHT.PK) 0.03

5931 Darwin Court, Carlsbad, California 92008

*Previously The Immune Response Corporation*
Orchestra Therapeutics is an immunopharmaceutical company focused on developing novel treatments for autoimmune and infectious diseases. Orchestra Therapeutics’ unique approach to controlling autoimmune diseases uses small peptide vaccines that appear to stimulate FOXP3+ Regulatory T-cells; a component of the immune system that is now recognized as being key in autoimmune pathogenesis. Rather than disrupting the function of the entire immune system, these therapeutic vaccines are designed to elicit a very specific response – akin to correcting one instrument in an orchestra that is out of tune – to help control disease.

Oxford Biomedica
(OXB.L) 9.70

Medawar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA UK 11622 El Camino Real #100, San Diego, CA 92130 USA

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of novel therapeutic vaccines and gene-based therapies with a focus on the areas of oncology and neurotherapy. Oxford BioMedica's products use genes as the mediators of a therapeutic effect and/or immune response. The Company’s gene therapy products deliver therapeutic molecules in vivo whilst its gene-based immunotherapy products deliver genes that recruit the patient’s immune system to mediate a therapeutic effect. The Company has a platform of gene delivery technologies that are predominantly based on highly engineered viral systems.

Phenomix

5871 Oberlin Drive, Suite 200, San Diego, CA 92121

Phenomix is a drug discovery and development company focused on addressing major unmet medical needs. The company invents and develops novel drugs to inhibit therapeutic targets in the protease and kinase families. Phenomix has a portfolio of programs underway in multiple indications. The most advanced programs are a Phase 2 inhibitor of the protease DPP4 for treatment of Type 2 diabetes and a preclinical program inhibiting NS3 protease for treatment of hepatitis C.

PhotoThera

2260 Rutherford Road, Suite 101, Carlsbad, CA 92008

PhotoThera is a privately owned biomedical company pioneering the emerging field of infrared energy therapeutics. The NeuroThera® System is an investigational device that seeks to improve neurological outcome via non-invasive delivery of a specific wavelength of infrared energy into the brain.

Prediction Sciences

9404 Genesee Avenue, La Jolla, CA 92037

Prediction Sciences is applying personal and genomic characteristics to improve patient care and safety in the prescribing of drugs. Our objective is to make the Prediction Sciences' RxIQ(TM) and GeneRx(TM) technology the industry standard for integrating the discoveries of pharmacogenomics into medical practice.

Prometheus Laboratories Inc.

9410 Carroll Park Drive, San Diego, CA 92121

Prometheus is a specialty pharmaceutical company committed to improving the lives of patients. Prometheus primarily focuses on the treatment, diagnosis and detection of gastrointestinal, autoimmune and inflammatory diseases and disorders. Prometheus’ strategy includes the marketing and delivery of pharmaceutical products complemented by its proprietary and patented high-value diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus provides physicians with a comprehensive approach to diagnosis and treatment for acute and chronic diseases.

Puracyp, Inc.
*VENDOR/SERVICE*

1989 Palomar Oaks Way, Suite B, Carlsbad, CA 92009

Puracyp is an industry leader dedicated to the development of cell lines useful for determining the ability of compounds to activate orphan nuclear receptors.

Santarus, Inc.
(SNTS) 2.75

10590 West Ocean Air Drive, Suite 200, San Diego, CA 92130

Santarus, Inc. is a specialty pharmaceutical company focused on acquiring, developing and commercializing products for the prevention & treatment of gastrointestinal diseases and disorders.

Sapient Discovery
*SERVICE*

0929 Technology Place, Suite B, San Diego, CA 92127

Sapient Discovery draws upon the extensive knowledge of its expert team of computational chemists and structural biologists who in the past have developed and successfully identified lead molecules for a wide range of protein targets some of which are in clinical trials and others in pre-clinical development. In order to meet the pharmaceutical industry’s need to quickly find drug leads from disease genes, Sapient Discovery computationally defines the molecular structure of potential drug targets from gene sequence information, using validated proprietary algorithms and experimental data from X-ray crystallography. The resulting protein structures can be used as templates for extremely rapid drug design. Sapient Discovery provides a unique and practical “operating system” that bridges the gap between novel target discovery and the 3-D structural coordinates required by chemists and biologists in order to discover new drugs from such targets.

Senomyx, Inc.
(SNMX) 4.03

4767 Nexus Centre Drive, San Diego, CA 92121

We have discovered or in-licensed many of the key receptors that mediate taste in humans. Having isolated human taste receptors, we have created proprietary taste receptor-based assay systems that provide a biochemical or electronic readout when a test compound affects the receptor. To enable faster compound discovery, we integrated our proprietary taste receptor-based screening assays into a robot-controlled automated system that uses plates containing an array of individual fluid wells, each of which can screen a different compound. Our receptor-based discovery and development process has enabled us to improve our ability to find novel flavor enhancers and taste modulators over the traditional use of simple taste tests. As a result, we have synthesized and discovered hundreds of unique potential flavor enhancers and taste modulators. The Company’s current flavor programs focus on the discovery and development of savory, sweet and salt flavor ingredients that are intended to allow for the reduction of MSG, sugar and salt in food and beverage products.

Sequenom, Inc.
(SQNM) 6.33

3595 John Hopkins Ct, San Diego CALIFORNIA 92024

SEQUENOM applies the power of human genetics to systematically identify disease-related genes that affect significant portions of the overall population. The pharmaceutical unit focuses on disease gene discovery, target identification, functional validation and ultimately diagnostic and therapeutic product development.

SGX Pharmaceuticals, Inc.
(SGXP) 0.00

10505 Roselle Street, San Diego, CA 92121

SGX Pharmaceuticals (formerly Structural GenomiX) is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. SGX's oncology pipeline includes drug candidates from its enabling, proprietary FAST™ drug discovery platform, such as next generation BCR-ABL inhibitors currently being developed in partnership with Novartis, MET tyrosine kinase inhibitors including SGX523, and lead series of potent JAK2 inhibitors.

Simpro Scientific
*VENDOR*

7949 Silverton, Suite 925, San Diego, CA 92126

SimPro Scientific delivers affordable solutions to simplify biotech processes. The scientists and engineers at Simpro Scientific have been producing recombinant products since the early 1990s. They have performed thousands of experiments using E. coli, culturing them in small shake flask experiments and scaling them up to large high density fermentations of hundreds of liters or more. They have purified the resulting products to pharmaceutical grade at multi-gram scales. In order to simplify their work, they spent countless hours developing products, unavailable elsewhere, to simplify their cell growth experiments and subsequent downstream processing. Some of these have resulted in in our standard products, while others are better categorized as custom ones. These unique products provide important boosts in product quality and personnel productivity. Simpro Scientific is very proud to offer these to you. Simpro stands firmly behind all of them and offers comprehensive warranties and guarantees.

Somaxon Pharmaceuticals, Inc.
*SPECIALTY/GENERIC*
(SOMX) 3.83

3721 Valley Centre Drive Suite 500, San Diego, CA 92130

Somaxon is a leading specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates in the fields of psychiatry and neurology.

Sterogene Bioseparations, Inc.
*VENDOR*

5922 Farnsworth Court, Carlsbad, California 92008

Sterogene Bioseparations is a cGMP manufacturer of chromatography resins. Our products include resins for removing endotoxin, viral purification resin, protein-A resins for Immunoglobulin purification, and activated resins for ligand immobilization.

Stratagene
*VENDOR*

11011 North Torrey Pines Rd, La Jolla, CA 92037

Stratagene, now an Agilent Technologies company, is a worldwide leader in developing innovative products and technologies for life science research. We support advances in science by inventing, manufacturing, and marketing products that simplify, accelerate and improve research. Since 1984, our products have been used throughout the academic, industrial, and government research sectors in fields spanning molecular biology, genomics, proteomics, drug discovery and toxicology.

Synbiotics Corporation

11011 Via Frontera, San Diego, CA 92127

SYNBIOTICS is a leading developer, manufacturer and marketer of diagnostic products dedicated to the worldwide companion and food animal industries. SYNBIOTICS produces highly sensitive and highly specific antigen (Avian Influenza Type A Antigen Test Kit) and antibody (ProFLOK® AIV ELISA) tests for on-site surveillance and early detection of Type A influenza in commercial poultry flocks.

Synthetic Genomics

9601 Blackwell Road, Suite 200, Rockville, MD 20850 11149 North Torrey Pines Road, Suite 100, La Jolla, CA 92037

*Synthetic Genomics, Inc., was founded by Dr. J. Craig Venter.*
The company is developing novel genomic-driven strategies to address global energy and environmental challenges. Recent advances in the field of synthetic genomics present seemingly limitless applications that could revolutionize production of energy, chemicals and pharmaceuticals and enable carbon sequestration and environmental remediation. Given our team’s longstanding history of pioneering science, we are uniquely positioned to ignite a biological industrial revolution, and we are committed to unlocking the keys to a clean energy future through genomics.

Takeda San Diego

10410 Science Center Drive, San Diego, CA 92121

Takeda San Diego (TSD) is Takeda's global center for excellence in structure-based drug discovery. TSD integrates cutting-edge protein crystallography and drug discovery technologies to efficiently generate Investigational New Drug (IND) candidates for the treatment of metabolic diseases and cancer. Multiple drug candidates discovered at TSD are currently in clinical trials including SYR322, a potential treatment for type II diabetes.

Targegen

9380 Judicial Drive, San Diego, CA 92121

TargeGen combines a focus on vascular biology with expertise in small molecule medicinal chemistry. TargeGen develops small-molecule multi target kinase inhibitors designed to reduce disease related increases in vascular permeability (edema), vascular proliferation (angiogenesis) and inflammation. These biological processes are associated with a broad range of human diseases including ischemic disorders, eye diseases (macular degeneration, diabetic macular edema, diabetic retinopathy) and various forms of cancer.

TorreyPines Therapeutics
(TPTX) 0.26

11085 N Torrey Pines Road, Suite 300, La Jolla, CA 92037

TorreyPines Therapeutics is committed to discovering, developing and commercializing novel small molecules to treat diseases and disorders of the central nervous system. Our therapeutic focus is in two areas: chronic pain, including migraine and neuropathic pain, and cognitive disorders, including cognitive impairment associated with schizophrenia and Alzheimer’s disease.

Verenium Corporation
(VRNM) 3.03

55 Cambridge Parkway Cambridge, MA 02142 4955 Directors Place, San Diego, CA 92121-1609

*Formed from merger of Diversa and Celunol in June 2007*
Verenium Corporation is developing new pathways to derive chemical building blocks from abundant, cellulosic biomass -- natural resources that are both renewable and widely distributed throughout the world. With its unique combination of expertise in enzymatic and fermentation technology, Verenium is developing new, lower-cost ways to produce these chemical building blocks and cost-effective, lower-impact substitutes. For example, Verenium’s fermentation process technology can be used to derive cheap sugars from common feedstocks for fuels production. Its DirectEvolution technology harnesses the power of enzymes to synthesize from living matter a wide range of novel compounds with unique properties tailored for specific applications. Verenium’s mission is to apply these technological capabilities to achieve industrial sustainability -- meeting the common needs of modern life from carbohydrates (the energy flows that are produced and stored in living biomass) rather than hydrocarbons (fossilized energy stocks that have been stored for countless millennia in the earth’s crust). Verenium’s innovative approach promises dramatic reductions in the carbon footprint of fuels production and other common industrial processes.

Vertex Pharmaceuticals, Inc.
(VRTX) 35.87

130 Waverly Street Cambridge, MA 02139 11010 Torreyana Road San Diego, CA 92121 88 Milton Park, Abingdon, Oxfordshire OX14 4RY UK

Vertex’s product pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and bacterial infection. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline. The Company is leading the development of the HCV protease inhibitor, telaprevir (VX-950)

Vical, Inc.
(VICL) 3.45

10390 Pacific Center Court, San Diego, CA 92121-4340

We research and develop biopharmaceutical products based on our patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The key discovery leading to our patented core technology was that muscle tissues can take up polynucleotide genetic material, such as DNA or RNA, directly, without the use of viral components or other delivery vehicles, and subsequently express the proteins encoded by the genetic material for periods ranging from weeks to more than a year. We often describe our approach as "DNA delivery technology" because it typically involves designing and constructing closed loops of DNA called plasmids, or pDNAs. These pDNAs contain a DNA segment encoding the protein of interest, as well as short segments of DNA that control protein expression. Plasmids can be manufactured using uniform methods of fermentation and processing. This could result in faster development times than technologies that require development of product-specific manufacturing processes.